Agios Pharmaceuticals

Agios Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
2008-01-01
Employees
386
Market Cap
$2.6B
Website
http://www.agios.com
Introduction

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is...

Clinical Trials
Related News

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: [14C]-AG-120
First Posted Date
2015-07-03
Last Posted Date
2015-12-14
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
8
Registration Number
NCT02489513
Locations
🇺🇸

Research Site, Madison, Wisconsin, United States

A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency

Phase 2
Active, not recruiting
Conditions
Pyruvate Kinase Deficiency
Interventions
Drug: AG-348
First Posted Date
2015-06-22
Last Posted Date
2024-12-19
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
52
Registration Number
NCT02476916
Locations
🇫🇷

Hôpital Saint-Vincent de Paul, Lille, Nord, France

🇳🇱

Universitair Medisch Centrum Utrecht, Utrecht, Netherlands

🇺🇸

Wayne State University School of Medicine - Children's Hospital of Michigan, Detroit, Michigan, United States

and more 10 locations

Food Effect Study of AG-221 in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: AG221
First Posted Date
2014-08-18
Last Posted Date
2015-12-14
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
30
Registration Number
NCT02218346

A Phase I Study of AG-348 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: Placebo
Drug: AG-348
First Posted Date
2014-05-29
Last Posted Date
2014-11-10
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
48
Registration Number
NCT02149966

A Phase I Study of AG-348 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: AG-348
Drug: Placebo
First Posted Date
2014-04-09
Last Posted Date
2014-10-22
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
48
Registration Number
NCT02108106
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy